Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Neoadjuvant Therapy in dMMR/MSI-H Colorectal Cancer
NCT05913570Phase 2Unknown
- Sponsor
- Liuying Biotech
- Start
- Jun 2023
- Primary completion
- Dec 2023
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in colorectal cancer (CRC), sponsored by Liuying Biotech. Primary endpoint: Pathological Complete Response Rate at 1 year. Status: unknown.
02
Drugs
cadonilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05913570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05913570.